Beta-blockers May Prevent Stress-induced Lung Cancer Treatment Resistance

Share this content:
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.
The results of this study support previous findings that psychological distress is associated with an increased risk of mortality among patients with lung cancer.

By attenuating treatment resistance, beta (β)-blockers may improve clinical outcomes among patients with non–small cell lung cancer (NSCLC) receiving an EGFR inhibitor, according to a hypothesis-generating study published in Science Translational Medicine.1

Though second- and third-generation EGFR inhibitors have efficacy against resistant disease caused by the T790M mutation, about 50% of patients have disease resistant because of another mechanism. This study evaluated stress hormones as a potential mechanism driving T790M-independent EGFR inhibitor resistance using in vitro techniques and assessed clinical outcomes using data from 3 clinical trials.

Preclinical Findings

“We knew from our previous studies that stress hormones cause dramatic increases in IL [interleukin]-6 in ovarian cancer cells. That led us to ask the question whether stress hormones could also increase IL-6 expression in NSCLC cells and in turn promote resistance to EGFR-targeted therapies,” Monique B. Nilsson, PhD, of the University of Texas MD Anderson Cancer Center in Houston, and lead author of the study, told Cancer Therapy Advisor.

The study demonstrated that EGFR tyrosine kinase inhibitor (TKI)–resistant NSCLC cell lines had significantly greater mRNA expression of IL-6 compared with nonresistant parental cells (P = .0005).

The stress hormones norepinephrine and epinephrine, as well as β-adrenergic agonists, induced IL-6 mRNA expression in the resistant NSCLC cell lines, but not in normal human bronchial epithelial cells. β-adrenergic antagonists, however, prevented norepinephrine from inducing IL-6 expression. 

In a xenograft mouse model, in which the EGFR TKI–resistant NSCLC cells were injected into mice, stress resulted in significantly higher IL-6 levels (P = .002) and over 2-fold greater tumor volumes (P ≤ .04) compared with mice who were not stressed. Xenograft mice treated with a β-adrenergic agonist also demonstrated greater levels of IL-6 mRNA.

Treatment of the xenograft mice with erlotinib resulted in tumor regression, but mice treated with erlotinib plus the β-adrenergic agonist became treatment resistant. The addition of a β-blocker or the anti-IL-6 antibody siltuximab to erlotinib and the β-adrenergic agonist, however, prevented the development of treatment resistance.

These data suggest that blocking the β-adrenergic receptor or IL-6 may prevent erlotinib resistance, even in the presence of a β-adrenergic agonist.

Page 1 of 3

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters